TrialPediatric diabetes2021

Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.

Tadej Battelino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.